Anti-EGFR/BRAF regimens outperformed other targeted combinations in pretreated patients, reinforcing that EGFR and BRAF are pivotal therapeutic targets for BRAF-mutated colorectal cancer. This evidence concerns the gene BRAF and colorectal cancer.